Solid-phase peptide synthesis explained

Why synthesis chemistry matters to a buyer

A certificate of analysis reports what came out of the process. Understanding the process itself explains why particular impurities appear, why some sequences are routinely available at 99 percent purity while others plateau lower, and why two vendors quoting the same purity figure can be selling materially different material.

Solid-phase peptide synthesis, introduced by Bruce Merrifield in 1963, remains the dominant route for sequences under roughly fifty residues. Every short research peptide in general circulation — BPC-157, TB-500 fragments, ipamorelin, GHK — is made this way. The alternative, recombinant expression, is reserved for longer chains such as IGF-1 LR3 where stepwise assembly becomes impractical.

The resin and the anchoring step

Synthesis begins at the C-terminus, the opposite direction to biological translation. The first amino acid is covalently attached to an insoluble polymer bead — commonly polystyrene cross-linked with divinylbenzene, or a polyethylene-glycol-grafted resin for difficult sequences. Because the growing chain is anchored to a solid support, excess reagents and by-products can be washed away by simple filtration at every step. That single design decision is what made automated peptide synthesis possible.

Resin choice also determines the C-terminal functionality of the finished peptide. Wang and 2-chlorotrityl resins release a free carboxylic acid on cleavage; Rink amide resin releases a C-terminal amide. This is not a cosmetic difference — a C-terminal amide changes the molecule's mass, charge and protease susceptibility, and is precisely the kind of detail that has to agree between the sequence on the label and the observed mass on the certificate.

Fmoc and Boc: two protecting-group strategies

Every amino acid brought into the reaction carries a temporary protecting group on its alpha-amino nitrogen so that only the intended bond forms. Two schemes dominate. Fmoc chemistry uses a base-labile fluorenylmethyloxycarbonyl group removed with piperidine, with acid-labile side-chain protection stripped at the end. Boc chemistry uses an acid-labile tert-butyloxycarbonyl group removed with trifluoroacetic acid, and requires hydrogen fluoride for final cleavage.

Fmoc is the modern default because its milder conditions avoid the specialised handling that hydrogen fluoride demands. Boc chemistry survives for sequences that are difficult under Fmoc conditions — highly aggregation-prone stretches, or peptides containing residues that do not tolerate repeated base exposure.

The coupling cycle and where yield is lost

Each residue is added in a two-step cycle: deprotect the alpha-amino group, then couple the next activated amino acid using a carbodiimide or an aminium/uronium reagent such as HBTU or HATU with a base. Wash steps separate the two. A modern automated synthesiser repeats this cycle in minutes.

The arithmetic of stepwise synthesis is unforgiving. Suppose each coupling proceeds at 99 percent efficiency — an excellent figure. Across a thirty-residue sequence the theoretical yield of full-length material is 0.99 raised to the twenty-ninth power, roughly 75 percent. The remaining quarter of the crude consists of deletion sequences missing one or more residues, plus truncated chains that failed to extend at all.

Certain sequences are worse. Stretches rich in beta-branched or hydrophobic residues aggregate on the resin, physically shielding the reactive terminus and dropping coupling efficiency well below 99 percent. Chemists mitigate this with pseudoproline dipeptides, backbone amide protection, elevated temperature or microwave assistance, but a difficult sequence remains difficult and is reflected in its price and in its typical achievable purity.

Cleavage, purification and lyophilization

When the chain is complete it is cleaved from the resin and the side-chain protecting groups are removed, typically with a trifluoroacetic acid cocktail containing scavengers that intercept the reactive cations released during deprotection. Without scavengers those cations re-attach to sensitive residues such as tryptophan, methionine and cysteine, producing adducts that show up as extra peaks in the chromatogram.

The crude peptide is then purified by preparative reversed-phase HPLC. This is the step that converts a 75 percent crude into a 98 or 99 percent product, and it is where most of the cost of a research peptide actually sits. Deletion sequences differ from the target by one residue, so they elute close to it; achieving high purity means sacrificing recovery by cutting the collected fraction narrowly.

Collected fractions are pooled, frozen and lyophilized. Because purification is performed in trifluoroacetic-acid-modified mobile phase, the isolated peptide is normally a trifluoroacetate salt — which is why net peptide content is always below the vial fill weight, and why that figure appears separately on a complete certificate.

What this predicts on a certificate

Knowing the route lets you read the analytics with expectations. Small satellite peaks eluting just before or after the main peak are almost always deletion sequences. A peak with a mass sixteen daltons above the target indicates oxidation, usually at methionine. Adducts differing by the mass of a protecting-group fragment point to incomplete scavenging during cleavage. A broad, poorly resolved main peak in a long or hydrophobic sequence suggests aggregation rather than impurity.

None of this replaces the analytical data. It tells you which questions to ask of it — and gives you a basis for judging whether a supplier's documentation is describing a real process or reproducing a template.